-
Schrodinger Inc NasdaqGS:SDGR Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Location: 1540 Broadway, 24th Floor, New York, NY, 10036, United States | Website: https://www.schrodinger.com | Industry: Health Information Services | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.161B
Cash
500.3M
Avg Qtr Burn
N/A
Short % of Float
18.48%
Insider Ownership
2.58%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SGR-2921 Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Data readout | |
SGR-3515 Details Solid tumor/s | Phase 1 Data readout | |
SGR-1505 Details Cancer, B-cell malignancies | Phase 1 Update |